Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-006697
Filing Date
2025-02-14
Accepted
2025-02-14 13:19:42
Documents
68
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2315314
2 ex31-1.htm EX-31.1 9597
3 ex32-1.htm EX-32.1 4666
  Complete submission text file 0001493152-25-006697.txt   9280702

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20241231.xsd EX-101.SCH 55722
5 XBRL CALCULATION FILE ppcb-20241231_cal.xml EX-101.CAL 62500
6 XBRL DEFINITION FILE ppcb-20241231_def.xml EX-101.DEF 261790
7 XBRL LABEL FILE ppcb-20241231_lab.xml EX-101.LAB 452050
8 XBRL PRESENTATION FILE ppcb-20241231_pre.xml EX-101.PRE 364835
71 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1450727
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-54878 | Film No.: 25626133
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)